TKNO · Alpha Teknova, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.08M | - | $10.45M | $10.29M | $9.79M | - | $9.58M | $9.61M | $9.29M | - |
| Cost of Revenue | $7.29M | - | $7.25M | $6.30M | $6.79M | - | $9.49M | $6.81M | $7.08M | - |
| Gross Profit | $3.78M | - | $3.21M | $3.98M | $3.01M | - | $90.0K | $2.80M | $2.21M | - |
| R&D | $609.0K | - | $542.0K | $581.0K | $552.0K | - | $627.0K | $678.0K | $860.0K | - |
| SG&A | $5.06M | - | $4.65M | $4.93M | $5.49M | - | $4.97M | $5.48M | $7.38M | - |
| Total Operating Expenses | $8.08M | - | $7.22M | $7.37M | $7.97M | - | $7.52M | $7.90M | $10.20M | - |
| D&A | $1.58M | - | $1.30M | $1.30M | $1.58M | - | $1.40M | $1.30M | $1.64M | - |
| Operating Income | ($4.30M) | - | ($4.02M) | ($3.39M) | ($4.96M) | - | ($7.43M) | ($5.10M) | ($7.99M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $47.0K | - | $79.0K | $19.0K | $22.0K | - | ($8.0K) | ($8.0K) | ($34.0K) | - |
| Net Income | ($4.55M) | - | ($4.29M) | ($3.57M) | ($4.64M) | - | ($7.57M) | ($5.36M) | ($8.10M) | - |
| EPS - Basic | ($0.08) | - | ($0.08) | ($0.07) | ($0.09) | - | ($0.15) | ($0.13) | ($0.20) | - |
| EPS - Diluted | ($0.08) | - | ($0.08) | ($0.07) | ($0.09) | - | ($0.15) | ($0.13) | ($0.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.31M | $5.91M | $3.20M | $3.28M | $3.38M | $3.71M | $6.14M | $18.60M | $21.60M | $28.48M |
| Accounts Receivable | $5.67M | $4.62M | $5.13M | $5.14M | $5.62M | $4.31M | $4.61M | $4.60M | $4.56M | $3.95M |
| Inventory | $6.87M | $7.05M | $6.91M | $7.61M | $6.57M | $6.80M | $7.67M | $10.99M | $11.21M | $11.59M |
| Accounts Payable | $1.62M | $1.38M | $1.08M | $1.20M | $1.55M | $825.0K | $975.0K | $1.02M | $1.54M | $1.49M |
| Current Assets | $31.67M | $34.51M | $36.56M | $38.06M | $39.73M | $42.78M | $45.93M | $35.28M | $38.82M | $45.66M |
| Total Assets | $98.66M | $103.58M | $107.63M | $110.49M | $113.99M | $118.77M | $124.10M | $115.35M | $120.82M | $128.59M |
| Current Liabilities | $6.90M | $7.54M | $6.94M | $6.48M | $7.04M | $11.21M | $9.72M | $7.41M | $7.04M | $8.88M |
| Long-term Debt | $13.17M | $13.12M | $13.08M | $13.03M | $12.99M | $9.44M | $10.86M | $12.27M | $13.18M | $13.25M |
| Total Liabilities | $33.73M | $34.81M | $34.98M | $34.43M | $35.39M | $36.38M | $36.83M | $36.42M | $37.44M | $38.55M |
| Stockholders' Equity | $64.92M | $68.78M | $72.65M | $76.06M | $78.61M | $82.39M | $87.27M | $78.93M | $83.38M | $90.04M |
| Retained Earnings | ($140.34M) | ($135.79M) | ($131.03M) | ($126.75M) | ($123.18M) | ($118.53M) | ($112.81M) | ($105.25M) | ($99.88M) | ($91.79M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.36M) | - | - | - | ($4.10M) | - | - | - | ($6.56M) | - |
| Investing Cash Flow | $1.84M | - | - | - | $3.82M | - | - | - | $13.0K | - |
| Financing Cash Flow | ($88.0K) | - | - | - | ($52.0K) | - | - | - | ($343.0K) | - |
| CapEx | $221.0K | - | - | - | $206.0K | - | - | - | $112.0K | - |
| Free Cash Flow | ($3.58M) | - | - | - | ($4.31M) | - | - | - | ($6.67M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 34.2% | - | 30.7% | 38.7% | 30.7% | - | 0.9% | 29.2% | 23.8% | - |
| Operating margin | -38.8% | - | -38.4% | -32.9% | -50.7% | - | -77.6% | -53.0% | -86.0% | - |
| EBITDA margin | -24.6% | - | -26.0% | -20.3% | -34.5% | - | -63.0% | -39.5% | -68.4% | - |
| Net margin | -41.1% | - | -41.0% | -34.7% | -47.4% | - | -79.0% | -55.8% | -87.2% | - |
| Free cash flow margin | -32.3% | - | - | - | -44.0% | - | - | - | -71.8% | - |
| FCF / Net income | 0.79 | - | - | - | 0.93 | - | - | - | 0.82 | - |
| R&D / Revenue | 5.5% | - | 5.2% | 5.6% | 5.6% | - | 6.5% | 7.1% | 9.3% | - |
| SG&A / Revenue | 45.7% | - | 44.5% | 47.9% | 56.1% | - | 51.9% | 57.0% | 79.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.6% | - | -4.0% | -3.2% | -4.1% | - | -6.1% | -4.7% | -6.7% | - |
| Return on equity | -7.0% | - | -5.9% | -4.7% | -5.9% | - | -8.7% | -6.8% | -9.7% | - |
| Return on invested capital | -4.3% | - | -3.7% | -3.0% | -4.3% | - | -6.0% | -4.4% | -6.5% | - |
| Liquidity | ||||||||||
| Current ratio | 4.59 | 4.58 | 5.27 | 5.87 | 5.64 | 3.82 | 4.73 | 4.76 | 5.52 | 5.14 |
| Quick ratio | 3.60 | 3.64 | 4.27 | 4.70 | 4.71 | 3.21 | 3.94 | 3.28 | 3.92 | 3.84 |
| Cash ratio | 0.62 | 0.78 | 0.46 | 0.51 | 0.48 | 0.33 | 0.63 | 2.51 | 3.07 | 3.21 |
| Leverage | ||||||||||
| Debt / Equity | 0.20 | 0.19 | 0.18 | 0.17 | 0.17 | 0.11 | 0.12 | 0.16 | 0.16 | 0.15 |
| Debt / Assets | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.08 | 0.09 | 0.11 | 0.11 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.52 | 1.51 | 1.48 | 1.45 | 1.45 | 1.44 | 1.42 | 1.46 | 1.45 | 1.43 |
| Liabilities / Assets | 0.34 | 0.34 | 0.32 | 0.31 | 0.31 | 0.31 | 0.30 | 0.32 | 0.31 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.10 | 0.09 | 0.09 | - | 0.08 | 0.08 | 0.08 | - |
| Inventory turnover | 1.06 | - | 1.05 | 0.83 | 1.03 | - | 1.24 | 0.62 | 0.63 | - |
| Days sales outstanding | 187d | - | 179d | 182d | 209d | - | 176d | 175d | 179d | - |
| Days inventory outstanding | 344d | - | 348d | 441d | 353d | - | 295d | 589d | 578d | - |
| Days payable outstanding | 81d | - | 55d | 70d | 84d | - | 38d | 55d | 80d | - |
| Cash conversion cycle | 450d | - | 473d | 553d | 479d | - | 433d | 709d | 677d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.4x | - | 4.6x | 3.5x | 3.5x | - | 2.9x | 0.7x | 1.3x | - |
| P / S | 14.0x | - | 31.7x | 25.5x | 28.3x | - | 26.2x | 5.8x | 11.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 13.1% | - | 9.2% | 7.0% | 5.4% | - | 17.2% | -16.6% | 1.9% | - |
| Revenue CAGR (3y) | 6.7% | - | -0.7% | -4.2% | 2.6% | - | 0.6% | 5.0% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 25.8% | - | 3462.2% | 42.1% | 36.1% | - | -93.9% | -44.7% | -8.8% | - |
| Operating income growth (YoY) | 13.4% | - | 45.9% | 33.6% | 37.8% | - | 15.2% | 27.1% | 10.7% | - |
| Net income growth (YoY) | 1.9% | - | 43.3% | 33.4% | 42.6% | - | 25.5% | 25.0% | 8.2% | - |
| EPS growth (YoY) | 11.1% | - | 46.7% | 46.2% | 55.0% | - | 55.9% | 40.9% | 0.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 16.9% | - | - | - | 35.4% | - | - | - | 44.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.4% | -16.5% | -16.8% | -3.6% | -5.7% | -8.5% | -12.4% | -8.4% | -9.5% | -9.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$40.52M totalLab Essentials$31.04M · 76.6%
Clinical Solutions$7.65M · 18.9%
Other Product$1.83M · 4.5%
Geographic
$40.52M totalUS$38.25M · 94.4%
Non Us$2.27M · 5.6%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Alpha Teknova against the 5 most active filers in the same SIC group.